PFE Beats Q3 Earnings & Sales Estimates, Raises 2026 Guidance
Pfizer (PFE) reported Q3 2026 adjusted EPS of $0.87, beating estimates of $0.72, with revenues of $16.58B, also surpassing expectations. Growth in Eliquis, Padcev, and other drugs offset declines in COVID-19 products. PFE raised 2026 guidance to $62.0B-$64.0B in revenue and $2.95-$3.05 in EPS, citing strong performance. Shares declined slightly in pre-market trading.
How this was made
The 30-second read
Why it matters
The quarter’s beat plus raised 2026 revenue and narrowed EPS range provide a concrete forward earnings revision catalyst, with product-level drivers (Eliquis, Padcev, Nurtec, Lorbrena, Vyndaqel) partially offset by COVID declines and Prevnar weakness.
Market read
Traders can update 2026 estimates immediately based on the raised revenue and adjusted EPS guidance ranges and the cited product mix drivers.
What to watch
Primary Care sales declined operationally and Prevnar missed estimates, so the guidance raise may rely heavily on Oncology and Specialty Care offsets rather than broad-based Primary Care recovery.
Background
Pfizer is transitioning away from declining COVID-related revenues and patent expirations, aiming to replace growth via launches, pipeline development, and acquisitions.
Ticker impact
Pfizer beat Q3 EPS and revenue estimates and raised 2026 revenue guidance to $62.0-$64.0B and adjusted EPS to $2.95-$3.05.
Likely upward bias as the market reprices 2026 growth expectations, partially offset by ongoing COVID revenue erosion.
The article provides fresh, company-specific guidance changes plus segment/product performance details that directly affect forward estimates.
Market effects
Reinforces a defensive pharma narrative where non-COVID product momentum can offset pandemic declines, potentially supporting large-cap pharma sentiment.
Primarily US large-cap pharma sentiment; limited direct regional spillover beyond healthcare indices.
International revenue growth and product mix shifts may influence global pharma peers’ read-through on demand outside the US.
Counterpoint
EPS guidance includes an approximately 10-cent-per-share unfavorable one-time acquired in-process R&D charge, so underlying earnings power may be less strong than headline guidance implies.
Key entities
- companyPfizer
Reported Q3 2026 results and raised 2026 revenue and adjusted EPS guidance.
- companyBristol Myers Squibb
Partnered on Eliquis alliance revenues referenced in Pfizer’s segment discussion.
- companyBioNTech
Partner for Comirnaty/COVID vaccine revenues referenced in Pfizer’s segment discussion.
- companyInnovent Biologics
Licensing and collaboration agreement tied to a one-time acquired in-process R&D charge affecting EPS guidance.
